Author:
Wang Yu,Wu Hailan,Wu Junzhen,Fan Yaxin,Liu Xiaofen,Li Yi,Hu Jiali,Zhang Jing,Guo Beining
Subject
Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry
Reference19 articles.
1. National Medical Products Administration, China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection(2021). https://www.nmpa.gov.cn/yaowen/ypjgyw/20210602083301144.html. (Accessed June 23, 2021).
2. In vivo antibacterial activity of MRX-I, a new oxazolidinone;Li;Antimicrob. Agents Chemother.,2014
3. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile;Gordeev;J. Med. Chem.,2014
4. In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe;Carvalhaes;Antimicrob. Agents Chemother.,2020
5. Looking for the new preparations for antibacterial therapy. V. New antimicrobial agents from the oxazolidinones groups in clinical trials;Karpiuk;Przegl. Epidemiol.,2017
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献